Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B

Table 4 Comparison between patients with and without sustained viral response (mean ± SD)

Parameter	SVR(+)(n = 18)	SVR (-)(n = 66)	P value
Male	13 (72.2)	47 (71.2)	NS
Female	5 (27.8)	19 (28.8)	NS
Age (yr)	35.3 ± 8.0	39.7 ± 10.8	NS
BMI (kg/m2)	26.5 ± 3.1	27.9 ± 4.5	NS
≥ 25	11 (61.1)	45 (68.2)	NS
Glucose (mg/dL)	97.4 ± 28.0	102.4 ± 25.5	NS
Cholesterol (mg/dL)	162.1 ± 23.7	175.6 ± 30.2	NS
Triglyceride (mg/dL)	109.7 ± 50.8	136.8 ± 28.5	NS
AST (IU/L)	117.2 ± 55.4	97.8 ± 28.5	NS
ALT (IU/L)	199.8 ± 82.0	122.3 ± 49.8	< 0.01
GGT (IU/L)	62.9 ± 69.9	46.4 ± 28.6	NS
ALP (IU/L)	93.4 ± 38.8	91.5 ± 22.4	NS
HBV-DNA (copies/mL × 104)	4961.6 ± 2245.1	5779.5 ± 13129.5	NS
HBeAg (+)	5 (27.8)	16 (24.2)	NS
HBeAg (-)	13 (72.2)	50 (75.8)	NS
Advanced fibrosis (score ≥ 3)	7 (38.9)	28 (42.4)	NS
Advanced HAI (score ≥ 9)	5 (27.8)	18 (27.8)	NS
Hepatosteatosis	2 (11.1)	17 (25.8)	NS

BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ glutamyl transferase; ALP: Alkaline phosphatase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HAI: Histological activity index; SVR: Sustained viral response. NS: Non significant.